12:17 PM EST - Resverlogix Corp. : Announced today the recent publication of an article titled: “ BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes ”, in the high-impact, peer-reviewed Clinical Epigenetics. Resverlogix Corp.
shares T.RVX are trading up $0.02 at $1.19.
